Plasmid News and Research

RSS

CRIPSR identifies cell-type-specific ACE2 modifiers

Researchers compile a list of candidate genes to identify the surface abundance of functional regulators of ACE2.

9 Mar 2022

Current progress in SARS-CoV-2 vaccine candidates

In a new study, researchers illustrated the current progress and obstacles in COVID-19 vaccine development.

7 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Researchers assess the efficacy of 8G3, a B-cell neutralizing antibody against SARS-CoV-2 variants, including the most recent Omicron variant.

3 Mar 2022

Study finds Omicron sublineage BA.2 is less pathogenic in rodent models than prior SARS-CoV-2 variants

Researchers evaluated the pathogenicity and replication potential of SARS-CoV-2 VOC Omicron lineage, BA.2 in immunocompetent mice and hamsters.

28 Feb 2022

Immunomolecular detection method to rapidly and accurately detect complete SARS-CoV-2 virions

Researchers developed a hybrid assay incorporating immunological antibody-based viral spike protein capture with molecular nucleic acid amplification by qRT-PCR.

24 Feb 2022

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Researchers recently evaluated the efficacy of the Oxford ChAdOx1 (AZD 1222/ AZD2816) vaccine against the Omicron, Delta, and Beta variants of SARS-CoV-2 in Syrian hamsters.

17 Feb 2022

Study explores the generation of SARS-CoV-2 Omicron Spike DNA construct using multiple site-targeted mutagenesis

In a new study, a team of researchers demonstrated multiple site-directed mutagenesis as an efficient, easy, and more economically viable alternative to commercial gene synthesis to highlight how specific residues can contribute to the molecular structure and functioning of proteins.

15 Feb 2022

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

A recent study demonstrated that intranasal (i.n.) delivery of COVID-19 vaccine in murine models elicits greater immune responses against the wildtype SARS-CoV-2 and its variants.

14 Feb 2022

New cloud-based repository creates a digital fingerprint of engineered microorganisms

A cloud-based repository that creates a digital fingerprint of engineered microorganisms has been successfully trialed.

9 Feb 2022

New method may be effective at quantifying DNA adenine methylation in complex organisms

For decades, a small group of cutting-edge medical researchers have been studying a biochemical, DNA tagging system, which switches genes on or off. Many have studied it in bacteria and now some have seen signs of it in, plants, flies, and even human brain tumors.

3 Feb 2022

SARS-CoV-2 protein NSP2 found to impair microRNA-induced gene silencing in human cells

In a new study, a team of researchers used co-immunoprecipitation and in vitro interaction assays to identify the molecular basis of interaction of SARS-CoV-2 non-structural protein 2 with eIF4E-homologous protein (4EHP)-GRB10-interacting glycine-tyrosine-phenylalanine domain protein 2 complex, involved in microRNA-mediated gene silencing in human cells.

1 Feb 2022

Impact of DNA clearance on mortality in patients with severe COVID-19 infections

In a new study, researchers conducted activity-based proteomic profiling of patients who had severe SARS-CoV-2 infections to understand the impact of DNA clearance on mortality.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Genome editing in vascular endothelial cells made possible with a powerful new delivery system

Northwestern Medicine scientists developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which line blood vessel walls.

16 Jan 2022

Cannabidiol may improve innate immune response against SARS-CoV-2

A recent study shows evidence that cannabidiol, an important active ingredient in the Cannabis sativa plant, can augment the antiviral innate immune response and prophylactically prime the innate antiviral response of cells – enabling in turn improved response against viruses such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Jan 2022

Virus-like particles as delivery vehicles for gene-editing

Scientists deliver gene-editing proteins through the use of engineered virus-like particles, which mediated efficient base editing both in vitro and in vivo.

13 Jan 2022

Exploring factors favoring transmission of SARS-CoV-2 Delta sublineage AY.4.2 over the Delta variant

In the present study, researchers isolated an infectious AY.4.2 strain of COVID-19 from the nasopharyngeal swab of a symptomatic individual from the Paris region. Then, they introduced the AY.4.2 signature mutations - T95I, Y145H, and A222V - in an expression plasmid coding the Delta protein to study the function of the AY.4.2 S protein.

13 Jan 2022

Curia unveils comprehensive mRNA solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle formulation and development for full-scale sterile fill-finish services.

From Curia Global, Inc. 7 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022